Practice Cases
Fracture Risk Assessment
Heidi Powell, MD Literature reviewed July 09, 2008. Updated January 22, 2009Click an answer under each question.
-
She has osteopenia, not osteoporosis, so is there any indication to start medication to prevent fractures?
- Option A Unclear, because more information about her risk factors is needed.
- Option B No, because her BMD is only -1.7 and treatment is indicated for those with a BMD of -2.5 or lower.
- Option C Yes, recent studies have shown that there may be a benefit to treating women with T scores between -1.5 and -2.5, regardless of risk factors.
-
Are there other risk factors besides personal history of fracture, smoking, or family history of osteoporosis which would encourage you to screen a postmenopausal woman prior to age 65?
-
With further questioning, you find out the following about your patient:
- Weight 150 pounds (height 65 inches)
- Alcohol: 3 glasses of wine each night
- No corticosteroid usage (past or present)
- No personal history of a fracture
- Smoking: 1 PPD
- No family history of a hip fracture
You decide to use the FRAX tool to determine her fracture risk given her many risk factors. You have a question about the FRAX tool as you are putting in the data.
Can the total hip BMD rather than the femoral neck BMD be used in the FRAX tool?
-
The FRAX tool requires either a yes or no response for some of the risk factors and does not allow for a dose or duration response. For example, our patient increased her drinking from one drink per night to 3 drinks per night only in the last 6 months.
How do you answer some of the clinical risk factor questions if you are unsure of the duration or amount?
-
The FRAX tool shows that her 10-year risk of having a fracture is:
- 14% for any major osteoporotic fracture
- 3.1% of a hip fracture.
Should you consider treating her?
-
If she were African-American with the same risk factors, would her fracture risk be the same?
-
If she were African-American, her 10-year hip fracture risk is 1.4 %. Does the cost-effective intervention threshold for osteoporosis treatment differ between races?